UBS analyst David Lai initiated coverage of Perspective Therapeutics (CATX) with a Buy rating and $20 price target The firm launched coverage of SMID cap biotech sector with a focus in oncology and autoimmune diseases. Its top pick is Syndax. Perspective has innovative radiopharmaceutical technology that is being “largely overlooked,” the analyst tells investors in a research note.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics presents updates at 37th Annual Congress of EANM
- Perspective begins shipping investigational products from facility in NJ
- Tesla lower after ‘underwhelming’ robotaxi launch event: Morning Buzz
- Perspective Therapeutics Inc trading resumes
- Perspective Therapeutics Inc trading halted, volatility trading pause